Does the media prefer FDMT or IMNM?

In the previous week, Immunome had 14 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 16 mentions for Immunome and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Immunome's score of 0.36 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 5 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FDMT or QURE?

In the previous week, uniQure had 4 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 6 mentions for uniQure and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat uniQure's score of 0.79 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or FDMT?

In the previous week, Trevi Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 3 mentions for Trevi Therapeutics and 2 mentions for 4D Molecular Therapeutics. Trevi Therapeutics' average media sentiment score of 1.35 beat 4D Molecular Therapeutics' score of 0.94 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or FDMT?

In the previous week, Nurix Therapeutics had 21 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 23 mentions for Nurix Therapeutics and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Nurix Therapeutics' score of 0.30 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 4 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FDMT or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat AbCellera Biologics' score of 0.70 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

4D Molecular Therapeutics (FDMT) Competitors

$11.30 -1.01 (-8.20%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$11.30 0.00 (0.00%)

As of 05:23 AM Eastern

Compare

FDMT vs. IMNM, QURE, TRVI, NRIX, and ABCL

Should you buy 4D Molecular Therapeutics stock or one of its competitors? MarketBeat compares 4D Molecular Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4D Molecular Therapeutics include Immunome (IMNM), uniQure (QURE), Trevi Therapeutics (TRVI), Nurix Therapeutics (NRIX), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does 4D Molecular Therapeutics compare to Immunome?

4D Molecular Therapeutics (NASDAQ:FDMT) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

4D Molecular Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the broader market. Comparatively, Immunome has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market.

4D Molecular Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.93	-$140.11M	-$2.57	N/A
Immunome	$6.94M	372.06	-$212.39M	-$2.38	N/A

Immunome has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Immunome	N/A	-51.15%	-47.32%

In the previous week, Immunome had 14 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 16 mentions for Immunome and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Immunome's score of 0.36 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	5 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

4D Molecular Therapeutics presently has a consensus price target of $29.88, indicating a potential upside of 164.38%. Immunome has a consensus price target of $33.17, indicating a potential upside of 45.47%. Given 4D Molecular Therapeutics' higher probable upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

4D Molecular Therapeutics beats Immunome on 10 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to uniQure?

4D Molecular Therapeutics (NASDAQ:FDMT) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

4D Molecular Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.93	-$140.11M	-$2.57	N/A
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A

4D Molecular Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the broader market. Comparatively, uniQure has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

4D Molecular Therapeutics presently has a consensus price target of $29.88, indicating a potential upside of 164.38%. uniQure has a consensus price target of $64.17, indicating a potential upside of 56.12%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

4D Molecular Therapeutics has a net margin of -182.34% compared to uniQure's net margin of -1,154.42%. 4D Molecular Therapeutics' return on equity of -36.83% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
uniQure	-1,154.42%	-145.81%	-27.15%

In the previous week, uniQure had 4 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 6 mentions for uniQure and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat uniQure's score of 0.79 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

4D Molecular Therapeutics beats uniQure on 12 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Trevi Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
4D Molecular Therapeutics	$85.21M	6.93	-$140.11M	-$2.57	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Trevi Therapeutics' return on equity of -24.53% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

In the previous week, Trevi Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 3 mentions for Trevi Therapeutics and 2 mentions for 4D Molecular Therapeutics. Trevi Therapeutics' average media sentiment score of 1.35 beat 4D Molecular Therapeutics' score of 0.94 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics presently has a consensus target price of $22.67, indicating a potential upside of 37.21%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 164.38%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Trevi Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, 4D Molecular Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the broader market.

Summary

Trevi Therapeutics beats 4D Molecular Therapeutics on 11 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Nurix Therapeutics presently has a consensus target price of $34.08, indicating a potential upside of 50.05%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 164.38%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nurix Therapeutics had 21 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 23 mentions for Nurix Therapeutics and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Nurix Therapeutics' score of 0.30 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4D Molecular Therapeutics has a net margin of -182.34% compared to Nurix Therapeutics' net margin of -928.44%. 4D Molecular Therapeutics' return on equity of -36.83% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

4D Molecular Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A
4D Molecular Therapeutics	$85.21M	6.93	-$140.11M	-$2.57	N/A

Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, meaning that its stock price is 170% more volatile than the broader market.

Summary

4D Molecular Therapeutics beats Nurix Therapeutics on 12 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to AbCellera Biologics?

4D Molecular Therapeutics (NASDAQ:FDMT) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

4D Molecular Therapeutics presently has a consensus price target of $29.88, suggesting a potential upside of 164.38%. AbCellera Biologics has a consensus price target of $8.00, suggesting a potential upside of 22.70%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, AbCellera Biologics had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat AbCellera Biologics' score of 0.70 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4D Molecular Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.93	-$140.11M	-$2.57	N/A
AbCellera Biologics	$75.13M	26.50	-$146.41M	-$0.48	N/A

AbCellera Biologics has a net margin of -181.75% compared to 4D Molecular Therapeutics' net margin of -182.34%. AbCellera Biologics' return on equity of -14.86% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

4D Molecular Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Summary

4D Molecular Therapeutics and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$643.52M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-4.40	19.17	27.11	24.26
Price / Sales	6.93	838.79	589.14	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	1.28	4.22	10.75	6.29
Net Income	-$140.11M	$64.26M	$3.58B	$330.66M
7 Day Performance	-11.86%	-3.58%	-2.10%	-1.35%
1 Month Performance	27.97%	2.12%	3.29%	-0.64%
1 Year Performance	157.99%	20.35%	26.32%	19.08%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	1.7984 of 5 stars	$11.30 -8.2%	$29.88 +164.4%	+164.0%	$643.52M	$85.21M	N/A	120
IMNM Immunome	3.2894 of 5 stars	$23.90 +1.2%	$33.17 +38.8%	+163.9%	$2.67B	$6.94M	N/A	40
QURE uniQure	3.7599 of 5 stars	$41.36 -1.1%	$64.17 +55.1%	+185.4%	$2.64B	$16.10M	N/A	500
TRVI Trevi Therapeutics	3.4732 of 5 stars	$17.95 +0.1%	$22.67 +26.3%	+152.2%	$2.55B	N/A	N/A	20	News Coverage Positive News
NRIX Nurix Therapeutics	3.5387 of 5 stars	$24.04 +0.3%	$32.20 +33.9%	+82.6%	$2.48B	$83.98M	N/A	300	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. IMNM, QURE, TRVI, NRIX, and ABCL

How does 4D Molecular Therapeutics compare to Immunome?

Summary

How does 4D Molecular Therapeutics compare to uniQure?

Summary

How does 4D Molecular Therapeutics compare to Trevi Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Nurix Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. IMNM, QURE, TRVI, NRIX, and ABCL

How does 4D Molecular Therapeutics compare to Immunome?

Which has more risk and volatility, FDMT or IMNM?

Which has higher valuation and earnings, FDMT or IMNM?

Is FDMT or IMNM more profitable?

Does the media prefer FDMT or IMNM?

Do institutionals and insiders have more ownership in FDMT or IMNM?

Do analysts prefer FDMT or IMNM?

Summary

How does 4D Molecular Therapeutics compare to uniQure?

Which has preferable valuation and earnings, FDMT or QURE?

Which has more volatility and risk, FDMT or QURE?

Do analysts rate FDMT or QURE?

Do institutionals and insiders have more ownership in FDMT or QURE?

Is FDMT or QURE more profitable?

Does the media refer more to FDMT or QURE?

Summary

How does 4D Molecular Therapeutics compare to Trevi Therapeutics?

Which has stronger valuation & earnings, TRVI or FDMT?

Do institutionals and insiders have more ownership in TRVI or FDMT?

Is TRVI or FDMT more profitable?

Does the media favor TRVI or FDMT?

Do analysts prefer TRVI or FDMT?

Which has more volatility & risk, TRVI or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Nurix Therapeutics?

Do analysts rate NRIX or FDMT?

Do insiders & institutionals have more ownership in NRIX or FDMT?

Does the media favor NRIX or FDMT?

Is NRIX or FDMT more profitable?

Which has higher valuation and earnings, NRIX or FDMT?

Which has more risk & volatility, NRIX or FDMT?

Summary

How does 4D Molecular Therapeutics compare to AbCellera Biologics?

Do analysts prefer FDMT or ABCL?

Does the media prefer FDMT or ABCL?

Which has higher valuation & earnings, FDMT or ABCL?

Is FDMT or ABCL more profitable?

Do institutionals and insiders hold more shares of FDMT or ABCL?

Which has more risk and volatility, FDMT or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools